Next Article in Journal
A Comparative Analysis of SARS-CoV-2 Variants of Concern (VOC) Spike Proteins Interacting with hACE2 Enzyme
Previous Article in Journal
Screen-Printed Electrodes—A Promising Tool for Antineoplastic Drug Detection (Cisplatin and Bleomycin) in Biological Samples
Previous Article in Special Issue
Identification and Validation of New DNA-PKcs Inhibitors through High-Throughput Virtual Screening and Experimental Verification
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 25
Issue 15
10.3390/ijms25158031
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Systematic Review of Naturally Derived Substances That Act as Inhibitors of the Nicotine Metabolizing Enzyme Cytochrome P450 2A6

by
Haralampos Tzoupis
1,
Konstantinos D. Papavasileiou
1,2,
Stavros Papatzelos
1,
Angelos Mavrogiorgis
1,
Lefteris C. Zacharia
3,
Georgia Melagraki
4 and
Antreas Afantitis
1,2,5,*
1
Department of ChemInformatics, NovaMechanics Ltd., Nicosia 1070, Cyprus
2
Department of ChemInformatics, NovaMechanics MIKE, 18545 Piraeus, Greece
3
School of Life and Health Sciences, University of Nicosia, Nicosia 1700, Cyprus
4
Division of Physical Sciences and Applications, Hellenic Military Academy, 16672 Vari, Greece
5
Division of Data Driven Innovation, Entelos Institute, Larnaca 6059, Cyprus
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2024, 25(15), 8031; https://doi.org/10.3390/ijms25158031
Submission received: 29 June 2024 / Revised: 20 July 2024 / Accepted: 21 July 2024 / Published: 23 July 2024
(This article belongs to the Special Issue Molecular Dynamics Simulation and Computer-Aided Screening of Natural Compounds)
Browse Figures
Versions Notes

Abstract

:
Tobacco smoking has been highlighted as a major health challenge in modern societies. Despite not causing death directly, smoking has been associated with several health issues, such as cardiovascular diseases, respiratory disorders, and several cancer types. Moreover, exposure to nicotine during pregnancy has been associated with adverse neurological disorders in babies. Nicotine Replacement Therapy (NRT) is the most common strategy employed for smoking cessation, but despite its widespread use, NRT presents with low success and adherence rates. This is attributed partially to the rate of nicotine metabolism by cytochrome P450 2A6 (CYP2A6) in each individual. Nicotine addiction is correlated with the high rate of its metabolism, and thus, novel strategies need to be implemented in NRT protocols. Naturally derived products are a cost-efficient and rich source for potential inhibitors, with the main advantages being their abundance and ease of isolation. This systematic review aims to summarize the natural products that have been identified as CYP2A6 inhibitors, validated through in vitro and/or in vivo assays, and could be implemented as nicotine metabolism inhibitors. The scope is to present the different compounds and highlight their possible implementation in NRT strategies. Additionally, this information would provide valuable insight regarding CYP2A6 inhibitors, that can be utilized in drug development via the use of in silico methodologies and machine-learning models to identify new potential lead compounds for optimization and implementation in NRT regimes.

1. Introduction

Tobacco smoking constitutes a significant public health risk worldwide and it is currently estimated that 1.3 billion people worldwide are using tobacco and tobacco products [1]. In Europe alone, based on the data reported by Eurostat, 19.7% of the population is considered a daily smoker [2]. Smoking has been implicated in cardiovascular diseases, respiratory disorders, and various types of cancer [3], as well as other debilitating conditions [4], while extended nicotine exposure in pregnancy has been associated with adverse neurodevelopmental disorders in babies [5,6,7,8]. The clinical data associated with tobacco smoking have led researchers to study the biochemistry of nicotine addiction and develop strategies to mitigate the problem and help people to quit smoking. Many different strategies have been developed regarding smoking cessation, including drug administration to prolong dopamine levels, psychological intervention [9,10,11], Nicotine Replacement Therapy (NRT) [12,13,14,15], or a combination. All these strategies aim at the gradual reduction in nicotine uptake through smoking and, consequently, to complete smoking cessation. NRT regimes appear to be the most effective of all these strategies, mainly due to their accessibility over-the-counter (OTC). One of the drawbacks regarding NRT success rates is poor adherence by smokers [16,17], while in other cases it can be attributed to the different rates of nicotine metabolism in each person by cytochrome P450 (CYP) [18,19]. Since nicotine is the substance that drives addiction to tobacco smoking [7,20,21], its pharmacokinetic and pharmacodynamic behavior has been the major focus for the development of drugs that can mitigate its action.
Nicotine metabolism has been extensively studied over the years, along with the role of cytochrome P450. The results have shown that the high rate of nicotine metabolism in smokers is correlated with increased nicotine uptake [20]. Smokers metabolize the majority of nicotine to cotinine, via the action of the CYP2A6 variant [22,23,24]. The correlation between CYP2A6 activity, nicotine metabolism, and smoking led researchers to investigate the role of various genetic CYP2A6 polymorphisms in nicotine addiction. Individuals that carry polymorphisms resulting in reduced CYP2A6 activity have a lower rate of nicotine metabolism compared to the normal (wild type) and are thus less nicotine dependent and smoke less [25,26]. At the same time, polymorphisms [alleles *1X2A, *1X2B (gene duplications), and *1B] that result in increased CYP2A6 activity compared to normal, have faster nicotine metabolism, causing individuals to smoke more, and lead to higher susceptibility to addiction [27,28,29].
CYP2A6 has similar structural characteristics to all the enzymes in the cytochrome P450 family. All members of the family contain a single heme moiety at the center of the active site [30,31], despite performing a variety of different functions. For instance, CYP2A6 is involved in the metabolism of foreign compounds that enter the cell, while other members of the family (e.g., CYP5A1) are involved in compound biosynthesis inside the cell [32]. The active site of CYP2A6 also contains residues such as Asn297 and Ile300 (Figure 1) that assist in the orientation of the nicotine alongside the iron atom of the heme [33]. The correct orientation of the ligand inside the active site expedites the catalytic reaction and thus increases the rate of metabolism. The polymorphisms that impact the activity of the enzyme appear to affect the expression of the protein or affect the structural characteristics of the enzyme [20,27,32].
NRT is usually ineffective due to these polymorphisms since NRT is not personalized to account for the different enzyme activities. Thus, inhibitors of the CYP2A6 enzyme have been proposed as a potential strategy for smoking cessation, especially for fast metabolizers, either independently or in conjunction with other NRT strategies [34,35]. A number of studies have tested this type of approach with the use of methoxsalen and coumarin derivatives [36,37,38,39]. The data have shown that methoxsalen has decreased nicotine metabolism in in vivo experiments [37] and in humans, resulting in a 24% decrease in cigarettes smoked compared to the placebo [39].
This approach has led researchers to explore all the potential options for developing safe and efficacious CYP2A6 inhibitors. Recent collaborative work has demonstrated that naturally occurring compounds can act as potential CYP2A6 inhibitors [35,40,41,42,43] and consequently, impede nicotine metabolism. The inclusion of dietary products that contain potential CYP2A6 inhibitors could serve as candidates for supplementing NRT regimes by mitigating nicotine uptake. For instance, flavonoids derived from the Gingko Biloba (GB) supplement inhibit the mouse P450 2A5 enzyme, which is the mouse ortholog for human 2A6 [42]. In fact, the naturally derived flavonoids presented similar inhibitory activity to that of cinnamaldehyde, another naturally derived metabolite, that has been shown to inhibit human 2A6 [43]. Natural products include a wide range of compounds, with diverse structures and chemical properties, with the potential to be used as natural P450 2A6 inhibitors. The structure-activity relationship (SAR) of natural compounds as inhibitors of cytochrome P450 2A6 involves understanding how different molecular structures and functional groups impact their inhibitory efficacy. Studies indicate that key interactions include hydrophobic forces, hydrogen bonding, and molecular geometry, which determine binding affinity and selectivity towards CYP2A6 [44,45,46]. Since inhibition of CYP2A6 has been experimentally proven a potential target for smoking reduction or smoking cessation, identifying all the natural compounds with P450 2A6 inhibitory potential is necessary to advance the relevant research. Accordingly, the scope of the systematic review is to identify the extent of current research regarding natural products that can inhibit nicotine metabolism. This review describes the natural products that have been studied as CYP2A6 inhibitors commenting on their action and highlighting their potential as a cost-efficient way to reduce nicotine addiction, either as stand-alone products or in combination with other NRT strategies.

2. Materials and Methods

2.1. Protocol and Registration

The systematic review was registered on the OSF database [https://osf.io/39e8f/ (accessed on 16 July 2024)] for systematic reviews with the DOI identifier 10.17605/OSF.IO/39E8F. The core of the review was stipulated as follows: “Which natural products have been experimentally investigated as potential CYP2A6 inhibitors?”. The Systematic Reviews and Meta-Analyses (PRISMAs) checklist were applied (Table S1) [47].

2.2. Eligibility Criteria

In the current review, we have included research articles and original papers containing chemical compounds that are natural products and have been experimentally tested (in vitro and in vivo) for potential CYP2A6 inhibition. All the publications examined were authored in English and can be readily accessible via public databases. Studies that contain no experimental data on the compounds or present ambiguous data are excluded.

2.3. Study Information Sources and Search Terms

All literature searches were performed via PubMed [48] and Scopus [49]. These databases include entries from international peer-reviewed journals and conference papers. The search on the databases was concluded in April 2024. The search terms employed for the search of abstracts, titles, and keywords were “natural products AND CYP2A6” and “natural products AND Cytochrome P450 2A6”.
The above combination of search terms was employed to retrieve all potential hits. By employing a more general search pattern instead of a very specific one (e.g., “natural products AND CYP2A6 AND inhibitor” or “natural products AND CYP2A6 AND inhibitor AND nicotine”), we aimed to incorporate as many publications as possible to avoid missing any relative literature. The broad specificity of the particular approach allows for the inclusion of papers that may contain relative information that otherwise may be discarded. The only drawback of the particular approach is the increased time required for filtering and screening of the results.

2.4. Study Selection

The titles and abstracts of papers obtained using the search terms described in Section 2.3 were collected and evaluated. All the publications that did not meet the eligibility criteria were omitted. The remaining papers were examined thoroughly and if they did not provide the necessary information, such as experimental validation, were excluded. The results of the search in both databases yielded a total of 659 literature items. The initial filtering process excluded all the items that did not fall into the category of original articles (e.g., books, reviews, short surveys, editorials, erratum, conference papers, etc.). The initial screening process resulted in 366 papers. The abstracts and titles of these papers were screened to remove any duplicates and papers that did not involve terms such as “inhibition” or did not provide any experimental data. The whole process led to the identification of 35 total papers that were examined in detail. The whole process was carried out by two people working independently to filter the results and is presented in Figure 2.

3. Results

Since the identification of CYP2A6 as a potential target for nicotine metabolism inhibition, there has been extensive research in the field. Natural products constitute an extensive library of compounds that cover a great variety of structures and chemical properties. In addition, natural products are a cost-efficient pool of compounds since they can either be easily isolated or they can be incorporated into the diet of a person without having to go under extensive pre-clinical and clinical investigation. The current systematic review has identified and grouped the natural and naturally derived products that have been experimentally tested for inhibition. The search resulted in an initial selection of 659 research articles (593 from Scopus and 66 from PubMed), reporting the effect of natural products on CYP2A6. The PRISMA flowchart (Figure 2) highlights the selection process of the different publications at each stage of the systematic review workflow. Regarding the results from the Scopus database (n = 593), the book chapters (n = 60), conference papers (n = 4), short surveys (n = 3), and reviews (n = 127) were excluded from the analysis as shown in Figure 2. Table 1 presents the major chemical groups of natural products that have shown CYP2A6 inhibitory activity based on the literature search, as described in Section 2, and Table S2 (Supplementary Information) contains the chemical structures of the different compounds, as well as the reported measured values for different inhibition attributes (IC50, Ki and % inhibition or remaining activity).
Based on the results of the search, as described above, certain studies were excluded (Table 2). The exclusion criteria for these studies were the absence of information about specific chemical structures that can act as CYP2A6 inhibitors and/or the absence of experimental data for CYP2A6 inhibition. As shown in Table 2, there are studies [61,71,72,73] that have looked at extracts derived from medicinal plants. In these studies, the authors did not consider or report on specific compounds present in the extracts and solely report on the extract’s effects on inhibition. An exception is the study by Rodeiro et al. (2013) [74], which reports the comparison between the plant extract from Mangifera indica (mango tree) and pure mangiferin (an ingredient derived from the plant). The rationale for excluding this study was that, even though pure mangiferin presented higher inhibitory activity than the extract, the overall inhibitory activity against CYP2A6 was weak, especially at lower concentrations (<250 μg/mL). Additionally, the study by Budzynska et al. (2016) [61] examined the impact of CYP2A6 inhibitors, like bergapten and 5-methoxypsoralen (5-MOP), on the motor functions of rats but only reports on the level of disruption in motor functions without any experimental information. Finally, Begas et al. (2018) [75] presented the results of a human in vivo study regarding the intake of Sideritis scardica decoction and the measured CYP2A6 inhibition.
The results of the literature search have produced a set of 105 compounds (Table 1 and Table S2) that have been experimentally tested as potential CYP2A6 inhibitors. The detailed screening of these papers showed that only 55 of the 105 compounds have demonstrated adequate inhibition of CYP2A6 with IC50 < 100 µM and/or Ki < 50 µM (Table S2). Moreover, it is important to note that the researchers in some of these studies have employed natural products as lead compounds in order to test their derivatives as well [65,66]. In the case of Fujita et al. (2001) [66], the authors investigated the activity of 23 organosulfur compounds against CYP2A6. The natural products in the paper comprised 10 compounds and from these, only dipropyl disulfide and diallyl disulfide exhibited potent inhibitory action against CYP2A6 [66]. Similarly, in the study by Qi et al. (2019), from the 17 coumarin derivatives that were investigated, only 7 were natural products [65]. These compounds represent only a tiny fraction of the number of naturally occurring substances. The structural diversity of the examined compounds correlates with the enzymatic function of the cytochrome to metabolize a variety of xenobiotics that enter the cell. In the case of nicotine uptake, the rate of its metabolism is proportional to the addiction caused to the individual. The increased clearance rate of nicotine leads to increased smoking and thus exposes the user to increased health risks.
Of the natural products examined, flavonoids (n = 9), coumarins (n = 7), and organosulfur compounds (n = 10) comprise the largest number of compounds with inhibitory activity. While organosulfur compounds exhibit characteristically diverse structures [80], flavonoid and coumarin derivatives typically contain at least a single benzopyrone moiety (Figure 3). The presence of the aromatic ring may potentially present similar properties to the ring structure of nicotine and thus could potentially explain the mechanism of action of these analogs. Both myricetin (IC50 = 41.4 µM) [58] and 6,7-dihydroxycoumarin (IC50 = 0.39 µM, Ki = 0.25 µM) [65] showed competitive binding to CYP2A6, while the coumarin analog presents a very high potency as a CYP2A6 inhibitor. This could be explained by the fact that CYP2A6 is specific for coumarin 7-hydroxylation activity [81]. Furthermore, the analysis carried out through molecular docking by Qi et al. (2019) showed that the binding of 6,7-dihydroxycoumarin closely resembles that of nicotine [65]. Based on their observations, the compound interacts with residues, such as Asn297, which have been highlighted as important to nicotine binding (Figure 1) [33]. These interactions orient the molecules almost perpendicular to the heme moiety of the cytochrome and could compete with nicotine. A similar mode of action may be inferred for myricetin; Tiong et al. (2010) suggested that the number of hydroxyl groups in the flavonoid skeleton increases the binding potential of the compound. In their study, the authors note that myricetin contains six –OH substituents, the highest number from all the flavonoids investigated [58].
Both myricetin and 6,7-dihydroxycoumarin are abundant in natural products. Myricetin, like most flavonoids, is found in various plants, tea, and fruits such as cranberries [82]. On the other hand, 6,7-dihydroxycoumarin is less commonly encountered and is primarily found in medicinal plants [83,84], such as Phellodendron amurense var. wilsonii [84] and Fraxinus rhynchophylla [85]. Similar to flavonoids, organosulfur compounds (Figure 3, middle) can be found in a variety of vegetables and roots (i.e., onion, garlic, broccoli, cabbage, etc.). These compounds are part of the diet of a great portion of the general population and thus can be easily incorporated into NRT strategies. Furthermore, in combination with the isothiocyanate group of compounds (Figure 3, bottom) they can have a potent role in CYP2A6 inhibition. Both isothiocyanate compounds reported present potent binding activity with an inhibitory constant (Ki) of 4.1 µM for BITC and 0.37 µM for PEITC [50]. The authors of this study state that both compounds inactivate the enzyme and prevent nicotine metabolism up to 80%. The proposed mode of action, as hypothesized in the paper, involves the binding of the compounds or other intermediates to the apoprotein form of CYP2A6 [50].
Many of the compounds reported have a moderate inhibition activity on CYP2A6, while there are compounds that present a weak inhibitory action against the enzyme. These compounds include aromatic aldehydes, such as vanillin and ethyl vanillin [67,86], and the furanocoumarin chalepensin [62], while cinnamaldehyde and benzaldehyde were found to be the most potent inhibitors of microsomal CYP2A6 of the flavoring agents tested in these studies. The two heavier aromatic aldehydes, namely vanillin and ethyl vanillin, exhibited significantly lower potency for microsomal recombinant CYP2A6 inhibition (Table 2 and Table S2). In a similar manner, the 1,4-naphthoquinone derivatives, rhinacanthin H and rhinacanthin I, presented inhibitory activity towards CYP2A6, and the authors have proposed that together with the other rhinacanthin derivatives these compounds may be considered as chemopreventive agents for smokers [63].
Another important consideration regarding natural products in NRT regimes is potential toxicity. Most of the compounds identified in this review do not exhibit high toxicity profiles. In most cases, very high concentrations are required to induce a toxic effect, and therefore, the majority of the compounds presented herein can be considered safe. Out of the 55 compounds identified, tryptamine has been shown to be potentially cytotoxic at concentrations found in many fermented foods (e.g., fish sauce, cheese) [87,88]. Safrole (Table S2) has also been reported to be moderately toxic in in vivo experiments and possibly carcinogenic to humans [89]. Moreover, cannabidiol and its derivatives have demonstrated cytotoxic effects on mouse Leydig cells [90], impact hepatic functions [91], and cause fertility issues [92]. In contrast, the alkaloid humantenine (Table S2), which is extracted from the Gelsemium spp. and employed in herbal remedies, exhibits increased toxicity [93]. On the other hand, coumarins, such as 8-methoxypsoralen (xanthotoxin) and bergapten, have shown very low toxicity, while presenting a wide variety of medicinal uses (e.g., anticancer, anti-inflammatory, and antimicrobial activity) [94,95]. Out of the flavonoid compounds, kaempferol (Table 1 and Table S2) has been identified to have potentially minor adverse effects on the liver in high concentrations [96,97]. Vanillin presented a favorable pharmacological profile, similar to 8-methoxypsoralen (xanthotoxin) with low toxicity [96,98], while showing the ability to inhibit or reduce the mutagenesis process initiated by xenobiotics [99].

4. Conclusions

Considering the studies mentioned in Section 3 and their findings, it is evident that natural products can offer a rich source of chemically diverse compounds. Based on the various experimental and cheminformatics tools, it is possible to investigate the potential action of natural products for CYP2A6 inhibition. Most approaches for smoking cessation have focused on developing de novo potent inhibitors of CYP2A6 and have utilized only a few naturally derived compounds as scaffolds for developing novel inhibitors. Identifying CYP2A6 inhibitors of natural origin is a cost-efficient way for the development of new products to be incorporated as enhancers of current NRTs, with the aim of increasing success rates. Most of the natural products can be marketed as food supplements and/or as effective medication with increased efficacy. Another benefit of natural products is their potential to serve as medication supplements, as they are associated with fewer side effects compared to current smoking cessation medicines like bupropion.
Moreover, the development of natural product libraries is presenting researchers access to thousands of compounds and scaffolds that can be easily isolated and employed in drug development. In this context, cheminformatic tools can be used to identify novel 2A6 inhibitors and screen the existing natural product databases for potential nicotine metabolism inhibitors. This is deemed necessary given that the current approach of testing natural/plant extracts one by one in the lab is time-consuming and costly. Subsequently, the identified compounds as the most suitable candidates capable of modulating nicotine consumption can be extensively tested in vitro and in vivo. In fact, there have been studies that employed natural compounds as scaffolds to synthesize potential CYP2A6 inhibitors [36,44,65,66,100]. Similarly, the structural basis of the naturally occurring coumarins provided insights into how modifications can improve efficacy in facilitating smoking cessation [36]. In all these cases, the reason behind choosing natural products as scaffolds was the favorable pharmacological profiles of the compounds, such as flavones and coumarins. Additionally, the candidate molecules can be utilized for further preclinical research as NRT enhancers, either in the form of food, dietary supplements, and/or medication, thus increasing NRT adherence and success rates. However, it is important to note that attention must be given to the toxicity profiles of the candidate molecules. As with most chemical substances, natural products can have harmful effects on human cells that are mediated by the intake concentration and the compound’s structure. Several natural products that have been explored for smoking cessation are known to inhibit CYP2A6, such as certain constituents found in grapefruit and other citrus fruits. These compounds can influence the metabolism of nicotine, potentially aiding in smoking cessation by prolonging nicotine’s effects. Nevertheless, there may be potential interactions with other medications, leading to adverse effects due to altered drug metabolism. While natural products in most food sources and traditional herbal remedies are generally considered safe, their potential to cause toxicity at higher doses or through prolonged use cannot be overlooked. This is particularly relevant when these natural products are used concurrently with other medications, as they might lead to unexpected drug interactions and side effects.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms25158031/s1. References [43,50,51,52,53,54,55,56,57,58,59,60,62,63,64,65,66,67,68,69,70,101,102,103,104,105,106,107,108,109,110,111,112,113,114] belongs to data in supplementary file.

Author Contributions

Conceptualization, A.A., G.M., H.T. and K.D.P.; methodology, H.T. and K.D.P.; formal analysis, H.T., K.D.P., S.P. and A.M.; writing—original draft preparation, H.T. and K.D.P.; writing—review and editing, H.T., K.D.P., S.P., L.C.Z. and A.A. All authors have read and agreed to the published version of the manuscript.

Funding

This work received funding from RNSMOKE ENTERPRISES/0223/Sub-call1/0262 project, co-funded by the European Regional Development Fund and the Republic of Cyprus through the Research and Innovation Foundation with additional support from EU H2020 project EthnoHERBS (grant agreement No. 823973).

Conflicts of Interest

H.T., K.D.P., S.P., A.M. and A.A. are employed by NovaMechanics Ltd., a cheminformatics company. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Ritchie, H.; Roser, M. Smoking. Our World Data 2023. 2023. Available online: https://ourworldindata.org/smoking (accessed on 5 March 2024).
  2. Statistics|Eurostat n.d. 2022. Available online: https://ec.europa.eu/eurostat/databrowser/product/page/HLTH_EHIS_SK1C (accessed on 4 March 2024).
  3. Dai, X.; Gil, G.F.; Reitsma, M.B.; Ahmad, N.S.; Anderson, J.A.; Bisignano, C.; Carr, S.; Feldman, R.; Hay, S.I.; He, J.; et al. Health effects associated with smoking: A Burden of Proof study. Nat. Med. 2022, 28, 2045–2055. [Google Scholar] [CrossRef]
  4. Kopa-Stojak, P.N.; Pawliczak, R. Comparison of the effects of active and passive smoking of tobacco cigarettes, electronic nicotine delivery systems and tobacco heating products on the expression and secretion of oxidative stress and inflammatory response markers. A systematic review. Inhal. Toxicol. 2024, 36, 1–15. [Google Scholar] [CrossRef]
  5. Wells, A.C.; Lotfipour, S. Prenatal nicotine exposure during pregnancy results in adverse neurodevelopmental alterations and neurobehavioral deficits. Adv. Drug Alcohol. Res. 2023, 3, 11628. [Google Scholar] [CrossRef]
  6. Mahabee-Gittens, E.M.; Harun, N.; Glover, M.; Folger, A.T.; Parikh, N.A.; Altaye, M.; Arnsperger, A.; Beiersdorfer, T.; Bridgewater, K.; et al.; Cincinnati Infant Neurodevelopment Early Prediction Study (CINEPS) Investigators Prenatal tobacco smoke exposure and risk for cognitive delays in infants born very premature. Sci. Rep. 2024, 14, 1397. [Google Scholar] [CrossRef]
  7. Hatsukami, D.K.; Luo, X.; Jensen, J.A.; al’Absi, M.; Allen, S.S.; Carmella, S.G.; Chen, M.; Cinciripini, P.M.; Denlinger-Apte, R.; Drobes, D.J.; et al. Effect of Immediate vs Gradual Reduction in Nicotine Content of Cigarettes on Biomarkers of Smoke Exposure: A Randomized Clinical Trial. JAMA 2018, 320, 880. [Google Scholar] [CrossRef]
  8. Froggatt, S.; Reissland, N.; Covey, J. The effects of prenatal cigarette and e-cigarette exposure on infant neurobehaviour: A comparison to a control group. EClinicalMedicine 2020, 28, 100602. [Google Scholar] [CrossRef]
  9. Stead, L.F.; Koilpillai, P.; Fanshawe, T.R.; Lancaster, T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst. Rev. 2016, 2016, CD008286. [Google Scholar] [CrossRef]
  10. De Santi, O.; Orellana, M.; Di Niro, C.A.; Greco, V. Evaluation of the effectiveness of cytisine for the treatment of smoking cessation: A systematic review and meta-analysis. Addiction 2024, 119, 649–663. [Google Scholar] [CrossRef]
  11. Deng, X.; Shang, X.; Guo, K.; Zhou, L.; Wang, Y.; Wu, Y.; Liang, S.; Fen, F.; Liu, W.; Wang, Z.; et al. Efficacy and safety of antidepressants for smoking cessation: A systematic review and network meta-analysis. Addict. Biol. 2023, 28, e13303. [Google Scholar] [CrossRef]
  12. Kim, S.S.; Prasad, A.; Nayak, M.M.; Chen, H.; Srisoem, C.; DeMarco, R.F.; Castaldi, P.; Cooley, M.E. Predictors of Nicotine Replacement Therapy Adherence: Mixed-Methods Research With a Convergent Parallel Design. Ann. Behav. Med. 2024, 58, kaae006. [Google Scholar] [CrossRef]
  13. Hartmann-Boyce, J.; Chepkin, S.C.; Ye, W.; Bullen, C.; Lancaster, T. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst. Rev. 2018, 2019, CD000146. [Google Scholar] [CrossRef] [PubMed]
  14. Theodoulou, A.; Chepkin, S.C.; Ye, W.; Fanshawe, T.R.; Bullen, C.; Hartmann-Boyce, J.; Livingstone-Banks, J.; Hajizadeh, A.; Lindson, N. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. 2023, 2023, CD013308. [Google Scholar] [CrossRef]
  15. Le Foll, B.; Piper, M.E.; Fowler, C.D.; Tonstad, S.; Bierut, L.; Lu, L.; Jha, P.; Hall, W.D. Tobacco and nicotine use. Nat. Rev. Dis. Primer 2022, 8, 19. [Google Scholar] [CrossRef] [PubMed]
  16. Mersha, A.G.; Eftekhari, P.; Bovill, M.; Tollosa, D.N.; Gould, G.S. Evaluating level of adherence to nicotine replacement therapy and its impact on smoking cessation: A protocol for systematic review and meta-analysis. BMJ Open 2020, 10, e039775. [Google Scholar] [CrossRef]
  17. Mersha, A.G.; Gould, G.S.; Bovill, M.; Eftekhari, P. Barriers and Facilitators of Adherence to Nicotine Replacement Therapy: A Systematic Review and Analysis Using the Capability, Opportunity, Motivation, and Behaviour (COM-B) Model. Int. J. Environ. Res. Public Health 2020, 17, 8895. [Google Scholar] [CrossRef] [PubMed]
  18. Lee, S.S.; Chang, Y.; Rigotti, N.A.; Singer, D.E.; Levy, D.E.; Tyndale, R.F.; Davis, E.M.; Freiberg, M.S.; King, S.; Wells, Q.S.; et al. Can Treatment Support Mitigate Nicotine Metabolism-Based Disparities in Smoking Abstinence? Secondary Analysis of the Helping HAND 4 Trial. Nicotine Tob. Res. 2023, 25, 1575–1584. [Google Scholar] [CrossRef]
  19. Jones, S.K.; Wolf, B.J.; Froeliger, B.; Wallace, K.; Carpenter, M.J.; Alberg, A.J. Nicotine Metabolism Predicted by CYP2A6 Genotypes in Relation to Smoking Cessation: A Systematic Review. Nicotine Tob. Res. 2022, 24, 633–642. [Google Scholar] [CrossRef]
  20. Murphy, S.E. Biochemistry of nicotine metabolism and its relevance to lung cancer. J. Biol. Chem. 2021, 296, 100722. [Google Scholar] [CrossRef]
  21. Benowitz, N.L. Pharmacology of Nicotine: Addiction, Smoking-Induced Disease, and Therapeutics. Annu. Rev. Pharmacol. Toxicol. 2009, 49, 57–71. [Google Scholar] [CrossRef]
  22. Gorrod, J.W.; Schepers, G. Biotransformation of nicotine in mammalian systems. In Analytical Determination of Nicotine and Related Compounds and Their Metabolites; Elsevier: Amsterdam, The Netherlands, 1999; pp. 45–67. [Google Scholar] [CrossRef]
  23. Hosono, H.; Kumondai, M.; Maekawa, M.; Yamaguchi, H.; Mano, N.; Oda, A.; Hirasawa, N.; Hiratsuka, M. Functional Characterization of 34 CYP2A6 Allelic Variants by Assessment of Nicotine C-Oxidation and Coumarin 7-Hydroxylation Activities. Drug Metab. Dispos. 2017, 45, 279–285. [Google Scholar] [CrossRef]
  24. Lee, H.; Kim, J.-H.; Han, S.; Lim, Y.-R.; Park, H.-G.; Chun, Y.-J.; Park, S.-W.; Kim, D. Directed-Evolution Analysis of Human Cytochrome P450 2A6 for Enhanced Enzymatic Catalysis. J. Toxicol. Environ. Health A 2014, 77, 1409–1418. [Google Scholar] [CrossRef] [PubMed]
  25. Chen, L.; Bloom, A.J.; Baker, T.B.; Smith, S.S.; Piper, M.E.; Martinez, M.; Saccone, N.; Hatsukami, D.; Goate, A.; Bierut, L. Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6). Addiction 2014, 109, 128–137. [Google Scholar] [CrossRef] [PubMed]
  26. Langlois, A.W.R.; El-Boraie, A.; Pouget, J.G.; Cox, L.S.; Ahluwalia, J.S.; Fukunaga, K.; Mushiroda, T.; Knight, J.; Chenoweth, M.J.; Tyndale, R.F.; et al. Genotyping, characterization, and imputation of known and novel CYP2A6 structural variants using SNP array data. J. Hum. Genet. 2023, 68, 533–541. [Google Scholar] [CrossRef] [PubMed]
  27. Tanner, J.-A.; Tyndale, R. Variation in CYP2A6 Activity and Personalized Medicine. J. Pers. Med. 2017, 7, 18. [Google Scholar] [CrossRef] [PubMed]
  28. Taghavi, T.; St.Helen, G.; Benowitz, N.L.; Tyndale, R.F. Effect of UGT2B10, UGT2B17, FMO3, and OCT2 genetic variation on nicotine and cotinine pharmacokinetics and smoking in African Americans. Pharm. Genom. 2017, 27, 143–154. [Google Scholar] [CrossRef] [PubMed]
  29. Mwenifumbo, J.C.; Tyndale, R.F. Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. Pharmacogenomics 2007, 8, 1385–1402. [Google Scholar] [CrossRef] [PubMed]
  30. Omura, T. Forty Years of Cytochrome P450. Biochem. Biophys. Res. Commun. 1999, 266, 690–698. [Google Scholar] [CrossRef] [PubMed]
  31. Guengerich, F.P. Human Cytochrome P450 Enzymes. In Cytochrome P450; Ortiz De Montellano, P.R., Ed.; Springer International Publishing: Cham, Switzerland, 2015; pp. 523–785. [Google Scholar] [CrossRef]
  32. Manikandan, P.; Nagini, S. Cytochrome P450 Structure, Function and Clinical Significance: A Review. Curr. Drug Targets 2018, 19, 38–54. [Google Scholar] [CrossRef] [PubMed]
  33. DeVore, N.M.; Scott, E.E. Nicotine and 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone Binding and Access Channel in Human Cytochrome P450 2A6 and 2A13 Enzymes. J. Biol. Chem. 2012, 287, 26576–26585. [Google Scholar] [CrossRef]
  34. Sellers, E.M.; Tyndale, R.F.; Fernandes, L.C. Decreasing smoking behaviour and risk through CYP2A6 inhibition. Drug Discov. Today 2003, 8, 487–493. [Google Scholar] [CrossRef]
  35. Deng, X.; Pu, Q.; Wang, E.; Yu, C. Celery extract inhibits mouse CYP2A5 and human CYP2A6 activities via different mechanisms. Oncol. Lett. 2016, 12, 5309–5314. [Google Scholar] [CrossRef]
  36. Yamaguchi, Y.; Nishizono, N.; Kobayashi, D.; Yoshimura, T.; Wada, K.; Kobayashi, K.; Oda, K. Synthesis and biological evaluation of coumarin derivatives as selective CYP2A6 inhibitors. Bioorg. Med. Chem. Lett. 2023, 86, 129206. [Google Scholar] [CrossRef] [PubMed]
  37. Ding, Z.-M.; Neslund, E.M.; Sun, D.; Tan, X. Methoxsalen Inhibits the Acquisition of Nicotine Self-Administration: Attenuation by Cotinine Replacement in Male Rats. Nicotine Tob. Res. 2024, ntae063. [Google Scholar] [CrossRef]
  38. Di, Y.; Chow, V.; Yang, L.-P.; Zhou, S.-F. Structure, Function, Regulation and Polymorphism of Human Cytochrome P450 2A6. Curr. Drug Metab. 2009, 10, 754–780. [Google Scholar] [CrossRef]
  39. Sellers, E. Inhibition of cytochrome P450 2A6 increases nicotine’s oral bioavailability and decreases smoking. Clin. Pharmacol. Ther. 2000, 68, 35–43. [Google Scholar] [CrossRef]
  40. Zuo, H.-L.; Huang, H.-Y.; Lin, Y.-C.-D.; Cai, X.-X.; Kong, X.-J.; Luo, D.-L.; Zhou, Y.-H.; Huang, H.-D. Enzyme Activity of Natural Products on Cytochrome P450. Molecules 2022, 27, 515. [Google Scholar] [CrossRef]
  41. Wang, Q.; Kuang, Y.; He, J.; Li, K.; Song, W.; Jin, H.; Qiao, X.; Ye, M. The prenylated phenolic natural product isoglycycoumarin is a highly selective probe for human cytochrome P450 2A6. Eur. J. Pharm. Sci. 2017, 109, 472–479. [Google Scholar] [CrossRef] [PubMed]
  42. Eleftheriou, C.; Zacharia, L.C. Ginkgo biloba L. flavonoids inhibit CYP 2A5; potential dietary supplement for nicotine replacement therapy enhancement. Nat. Prod. Res. 2022, 36, 4210–4214. [Google Scholar] [CrossRef] [PubMed]
  43. Chan, J.; Oshiro, T.; Thomas, S.; Higa, A.; Black, S.; Todorovic, A.; Elbarbry, F.; Harrelson, J.P. Inactivation of CYP2A6 by the Dietary Phenylpropanoid trans-Cinnamic Aldehyde (Cinnamaldehyde) and Estimation of Interactions with Nicotine and Letrozole. Drug Metab. Dispos. 2016, 44, 534–543. [Google Scholar] [CrossRef]
  44. Rahnasto, M.; Raunio, H.; Poso, A.; Wittekindt, C.; Juvonen, R.O. Quantitative Structure−Activity Relationship Analysis of Inhibitors of the Nicotine Metabolizing CYP2A6 Enzyme. J. Med. Chem. 2005, 48, 440–449. [Google Scholar] [CrossRef]
  45. Roy, K.; Roy, P.P. Exploring QSAR and QAAR for inhibitors of cytochrome P450 2A6 and 2A5 enzymes using GFA and G/PLS techniques. Eur. J. Med. Chem. 2009, 44, 1941–1951. [Google Scholar] [CrossRef] [PubMed]
  46. Gharaghani, S.; Khayamian, T.; Keshavarz, F. Docking, molecular dynamics simulation studies, and structure-based QSAR model on cytochrome P450 2A6 inhibitors. Struct. Chem. 2012, 23, 341–350. [Google Scholar] [CrossRef]
  47. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021, 372, n71. [Google Scholar] [CrossRef] [PubMed]
  48. PubMed n.d. Available online: https://pubmed.ncbi.nlm.nih.gov/?db=PubMed (accessed on 24 April 2024).
  49. Scopus Preview—Scopus—Welcome to Scopus, n.d. Available online: https://www.scopus.com/home.uri (accessed on 24 April 2024).
  50. Von Weymarn, L.B.; Chun, J.A.; Hollenberg, P.F. Effects of benzyl and phenethyl isothiocyanate on P450s 2A6 and 2A13: Potential for chemoprevention in smokers. Carcinogenesis 2006, 27, 782–790. [Google Scholar] [CrossRef] [PubMed]
  51. Srovnalova, A.; Vanduchova, A.; Svecarova, M.; Anzenbacherova, E.; Tomankova, V.; Anzenbacher, P.; Dvorak, Z. Effects of sulforaphane and its S- and R-enantiomers on the expression and activities of human drug-metabolizing cytochromes P450. J. Funct. Foods 2015, 14, 487–501. [Google Scholar] [CrossRef]
  52. Kramlinger, V.M.; Von Weymarn, L.B.; Murphy, S.E. Inhibition and inactivation of cytochrome P450 2A6 and cytochrome P450 2A13 by menthofuran, β-nicotyrine and menthol. Chem. Biol. Interact. 2012, 197, 87–92. [Google Scholar] [CrossRef]
  53. Stephens, E.S.; Walsh, A.A.; Scott, E.E. Evaluation of Inhibition Selectivity for Human Cytochrome P450 2A Enzymes. Drug Metab. Dispos. 2012, 40, 1797–1802. [Google Scholar] [CrossRef] [PubMed]
  54. Endo, T.; Ban, M.; Hirata, K.; Yamamoto, A.; Hara, Y.; Momose, Y. Involvement of CYP2A6 in the Formation of a Novel Metabolite, 3-Hydroxypilocarpine, from Pilocarpine in Human Liver Microsomes. Drug Metab. Dispos. 2007, 35, 476–483. [Google Scholar] [CrossRef] [PubMed]
  55. Kinonen, T.; Pasanen, M.; Gynther, J.; Poso, A.; Järvinen, T.; Alhava, E.; Juvonen, R.O. Competitive inhibition of coumarin 7-hydroxylation by pilocarpine and its interaction with mouse CYP 2A5 and human CYP2A6. Br. J. Pharmacol. 1995, 116, 2625–2630. [Google Scholar] [CrossRef] [PubMed]
  56. Pelkonen, O.; Turpeinen, M.; Hakkola, J.; Honkakoski, P.; Hukkanen, J.; Raunio, H. Inhibition and induction of human cytochrome P450 enzymes: Current status. Arch. Toxicol. 2008, 82, 667–715. [Google Scholar] [CrossRef]
  57. Bojić, M.; Kondža, M.; Rimac, H.; Benković, G.; Maleš, Ž. The Effect of Flavonoid Aglycones on the CYP1A2, CYP2A6, CYP2C8 and CYP2D6 Enzymes Activity. Molecules 2019, 24, 3174. [Google Scholar] [CrossRef] [PubMed]
  58. Tiong, K.H.; Yiap, B.C.; Tan, E.L.; Ismail, R.; Ong, C.E. In vitro modulation of naturally occurring flavonoids on cytochrome P450 2A6 (CYP2A6) activity. Xenobiotica 2010, 40, 458–466. [Google Scholar] [CrossRef] [PubMed]
  59. Boonruang, S.; Prakobsri, K.; Pouyfung, P.; Srisook, E.; Prasopthum, A.; Rongnoparut, P.; Sarapusit, S. Inhibition of human cytochromes P450 2A6 and 2A13 by flavonoids, acetylenic thiophenes and sesquiterpene lactones from Pluchea indica and Vernonia cinerea. J. Enzyme Inhib. Med. Chem. 2017, 32, 1136–1142. [Google Scholar] [CrossRef]
  60. Draper, A.J.; Madan, A.; Parkinson, A. Inhibition of Coumarin 7-Hydroxylase Activity in Human Liver Microsomes. Arch. Biochem. Biophys. 1997, 341, 47–61. [Google Scholar] [CrossRef] [PubMed]
  61. Budzynska, B.; Skalicka-Wozniak, K.; Kruk-Slomka, M.; Wydrzynska-Kuzma, M.; Biala, G. In vivo modulation of the behavioral effects of nicotine by the coumarins xanthotoxin, bergapten, and umbelliferone. Psychopharmacology 2016, 233, 2289–2300. [Google Scholar] [CrossRef] [PubMed]
  62. Ueng, Y.; Chen, C.; Chung, Y.; Liu, T.; Chang, Y.; Lo, W.; Murayama, N.; Yamazaki, H.; Souček, P.; Chau, G.; et al. Mechanism-based inhibition of cytochrome P450 (CYP)2A6 by chalepensin in recombinant systems, in human liver microsomes and in mice in vivo. Br. J. Pharmacol. 2011, 163, 1250–1262. [Google Scholar] [CrossRef] [PubMed]
  63. Pouyfung, P.; Prasopthum, A.; Sarapusit, S.; Srisook, E.; Rongnoparut, P. Mechanism-based Inactivation of Cytochrome P450 2A6 and 2A13 by Rhinacanthus nasutus Constituents. Drug Metab. Pharmacokinet. 2014, 29, 75–82. [Google Scholar] [CrossRef] [PubMed]
  64. Jeong, S.; Woo, M.M.; Flockhart, D.A.; Desta, Z. Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4′-methanol-bisbenzonitrile in vitro. Cancer Chemother. Pharmacol. 2009, 64, 867–875. [Google Scholar] [CrossRef] [PubMed]
  65. Qi, X.; Dou, T.; Wang, Z.; Wu, J.; Yang, L.; Zeng, S.; Deng, M.; Lü, M.; Liang, S. Inhibition of human cytochrome P450 2A6 by 7-hydroxycoumarin analogues: Analysis of the structure-activity relationship and isoform selectivity. Eur. J. Pharm. Sci. 2019, 136, 104944. [Google Scholar] [CrossRef]
  66. Fujita, K.; Kamataki, T. Screening of organosulfur compounds as inhibitors of human CYP2A6. Drug Metab. Dispos. Biol. Fate Chem. 2001, 29, 983–989. [Google Scholar]
  67. Winters, B.R.; Kochar, T.K.; Clapp, P.W.; Jaspers, I.; Madden, M.C. Impact of E-Cigarette Liquid Flavoring Agents on Activity of Microsomal Recombinant CYP2A6, the Primary Nicotine-Metabolizing Enzyme. Chem. Res. Toxicol. 2020, 33, 1689–1697. [Google Scholar] [CrossRef] [PubMed]
  68. Nasrin, S.; Coates, S.; Bardhi, K.; Watson, C.; Muscat, J.E.; Lazarus, P. Inhibition of Nicotine Metabolism by Cannabidiol (CBD) and 7-Hydroxycannabidiol (7-OH-CBD). Chem. Res. Toxicol. 2023, 36, 177–187. [Google Scholar] [CrossRef] [PubMed]
  69. Yamaori, S.; Maeda, C.; Yamamoto, I.; Watanabe, K. Differential inhibition of human cytochrome P450 2A6 and 2B6 by major phytocannabinoids. Forensic Toxicol. 2011, 29, 117–124. [Google Scholar] [CrossRef]
  70. Ueng, Y.-F.; Hsieh, C.-H.; Don, M.-J. Inhibition of human cytochrome P450 enzymes by the natural hepatotoxin safrole. Food Chem. Toxicol. 2005, 43, 707–712. [Google Scholar] [CrossRef] [PubMed]
  71. Lim, S.Y.M.; Alshagga, M.A.; Alshawsh, M.A.; Ong, C.E.; Pan, Y. In vitro effects of 95% khat ethanol extract (KEE) on human recombinant cytochrome P450 (CYP)1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2E1, CYP2J2 and CYP3A5. Drug. Metab. Pers. Ther. 2022, 37, 55–67. [Google Scholar] [CrossRef] [PubMed]
  72. Ma, W.; Wang, W.; Huang, X.; Yao, G.; Jia, Q.; Shen, J.; Ouyang, H.; Chang, Y.; He, J. HPLC-MS/MS Analysis of Aconiti Lateralis Radix Praeparata and Its Combination with Red Ginseng Effect on Rat CYP450 Activities Using the Cocktail Approach. Evid. Based Complement. Alternat Med. 2020, 2020, 1–12. [Google Scholar] [CrossRef] [PubMed]
  73. Showande, J.S.; Igbinoba, S.I.; Kajula, M.; Hokkanen, J.; Tolonen, A.; Adegbolagun, O.M.; Fakeye, T.O. In vitro modulation of cytochrome P450 isozymes and pharmacokinetics of caffeine by extracts of Hibiscus sabdariffa Linn calyx. J. Basic. Clin. Physiol. Pharmacol. 2019, 30, 20180206. [Google Scholar] [CrossRef]
  74. Rodeiro, I.; José Gómez-Lechón, M.; Perez, G.; Hernandez, I.; Herrera, J.A.; Delgado, R.; Castell, J.V.; Teresa Donato, M. Mangifera indica L. Extract and Mangiferin Modulate Cytochrome P450 and UDP-Glucuronosyltransferase Enzymes in Primary Cultures of Human Hepatocytes. Phytother. Res. 2013, 27, 745–752. [Google Scholar] [CrossRef] [PubMed]
  75. Begas, E.; Kilindris, T.; Kouvaras, E.; Tsioutsioumi, A.; Kouretas, D.; Asprodini, E.K. Dietary effects of Sideritis scardica “mountain tea” on human in vivo activities of xenobiotic metabolizing enzymes in healthy subjects. Food Chem. Toxicol. 2018, 122, 38–48. [Google Scholar] [CrossRef]
  76. Wan, X.; Ji, H.; Ma, H.; Yang, Z.; Li, N.; Chen, X.; Chen, Y.; Yang, H.; Wang, Z. Lycopene alleviates aflatoxin B 1 induced liver damage through inhibiting cytochrome 450 isozymes and improving detoxification and antioxidant systems in broiler chickens. Ital. J. Anim. Sci. 2022, 21, 31–40. [Google Scholar] [CrossRef]
  77. Zhang, J.; Qi, M.; Shi, M.; Chen, J.; Zhang, X.; Yang, J.; Zhang, K.; Han, Y.; Guo, C. Effects of Danhong injection, a traditional Chinese medicine, on nine cytochrome P450 isoforms in vitro. Biomed. Chromatogr. 2019, 33, e4454. [Google Scholar] [CrossRef]
  78. Showande, S.J.; Fakeye, T.O.; Kajula, M.; Hokkanen, J.; Tolonen, A. Potential inhibition of major human cytochrome P450 isoenzymes by selected tropical medicinal herbs—Implication for herb–drug interactions. Food Sci. Nutr. 2019, 7, 44–55. [Google Scholar] [CrossRef]
  79. Fasinu, P.S.; Gutmann, H.; Schiller, H.; James, A.-D.; Bouic, P.J.; Rosenkranz, B. The Potential of Sutherlandia frutescens for Herb-Drug Interaction. Drug Metab. Dispos. 2013, 41, 488–497. [Google Scholar] [CrossRef]
  80. Ruhee, R.T.; Roberts, L.A.; Ma, S.; Suzuki, K. Organosulfur Compounds: A Review of Their Anti-inflammatory Effects in Human Health. Front. Nutr. 2020, 7, 64. [Google Scholar] [CrossRef]
  81. Pelkonen, O.; Rautio, A.; Raunio, H.; Pasanen, M. CYP2A6: A human coumarin 7-hydroxylase. Toxicology 2000, 144, 139–147. [Google Scholar] [CrossRef]
  82. Imran, M.; Saeed, F.; Hussain, G.; Imran, A.; Mehmood, Z.; Gondal, T.A.; El-Ghorab, A.; Ahmad, I.; Pezzani, R.; Arshad, M.U.; et al. Myricetin: A comprehensive review on its biological potentials. Food Sci. Nutr. 2021, 9, 5854–5868. [Google Scholar] [CrossRef]
  83. Anywar, G.; Muhumuza, E. Bioactivity and toxicity of coumarins from African medicinal plants. Front. Pharmacol. 2024, 14, 1231006. [Google Scholar] [CrossRef]
  84. Wu, T.-S.; Hsu, M.-Y.; Kuo, P.-C.; Sreenivasulu, B.; Damu, A.G.; Su, C.-R.; Li, C.-Y.; Chang, H.-C.; Chang, H.-C. Constituents from the Leaves of Phellodendron a murense var. w ilsonii and Their Bioactivity. J. Nat. Prod. 2003, 66, 1207–1211. [Google Scholar] [CrossRef]
  85. Zhang, L.; Xie, Q.; Li, X. Esculetin: A review of its pharmacology and pharmacokinetics. Phytother. Res. 2022, 36, 279–298. [Google Scholar] [CrossRef]
  86. Song, X.; Porter, M.E.; Whitaker, V.M.; Lee, S.; Wang, Y. Identification of ethyl vanillin in strawberry (Fragaria × ananassa) using a targeted metabolomics strategy: From artificial to natural. Food Chem. X 2023, 20, 100944. [Google Scholar] [CrossRef]
  87. Del Rio, B.; Redruello, B.; Fernandez, M.; Martin, M.C.; Ladero, V.; Alvarez, M.A. The biogenic amine tryptamine, unlike β-phenylethylamine, shows in vitro cytotoxicity at concentrations that have been found in foods. Food Chem. 2020, 331, 127303. [Google Scholar] [CrossRef]
  88. Paley, E.; Perry, G.; Sokolova, O. Tryptamine Induces Axonopathy and Mitochondriopathy Mimicking Neurodegenerative Diseases via Tryptophanyl-tRNA Deficiency. Curr. Alzheimer Res. 2013, 10, 987–1004. [Google Scholar] [CrossRef]
  89. Götz, M.E.; Sachse, B.; Schäfer, B.; Eisenreich, A. Myristicin and Elemicin: Potentially Toxic Alkenylbenzenes in Food. Foods 2022, 11, 1988. [Google Scholar] [CrossRef]
  90. Li, Y.; Wu, Q.; Li, X.; Cournoyer, P.; Choudhuri, S.; Guo, L.; Chen, S. Toxicity of cannabidiol and its metabolites in TM3 mouse Leydig cells: A comparison with primary human Leydig cells. Arch. Toxicol. 2024. [CrossRef]
  91. Chen, S.; Li, Y.; Li, X.; Wu, Q.; Puig, M.; Moulin, F.; Gingrich, J.; Guo, L. Metabolism and liver toxicity of cannabidiol. J. Environ. Sci. Health Part C 2024, 1–17. [Google Scholar] [CrossRef]
  92. Neradugomma, N.K.; Drafton, K.; Mor, G.G.; Mao, Q. Marijuana-derived cannabinoids inhibit uterine endometrial stromal cell decidualization and compromise trophoblast-endometrium cross-talk. Reprod. Toxicol. 2019, 87, 100–107. [Google Scholar] [CrossRef]
  93. Marileo, A.M.; Lara, C.O.; Sazo, A.; Contreras, O.V.; González, G.; Castro, P.A.; Aguayo, L.G.; Moraga-Cid, G.; Fuentealba, J.; Burgos, C.F.; et al. Molecular Pharmacology of Gelsemium Alkaloids on Inhibitory Receptors. Int. J. Mol. Sci. 2024, 25, 3390. [Google Scholar] [CrossRef]
  94. Wu, A.; Lu, J.; Zhong, G.; Lu, L.; Qu, Y.; Zhang, C. Xanthotoxin (8-methoxypsoralen): A review of its chemistry, pharmacology, pharmacokinetics, and toxicity. Phytother. Res. 2022, 36, 3805–3832. [Google Scholar] [CrossRef]
  95. Young, A.R.; Walker, S.L.; Kinley, J.S.; Plastow, S.R.; Averbeck, D.; Morlière, P.; Dubertret, L. Phototumorigenesis studies of 5-methoxypsoralen in bergamot oil: Evaluation and modification of risk of human use in an albino mouse skin model. J. Photochem. Photobiol. B 1990, 7, 231–250. [Google Scholar] [CrossRef]
  96. De Oliveira, R.T.; Da Silva Oliveira, J.P.; Da Silva, A.L.M.; Carrão Dantas, E.K.; Koblitz, M.G.B.; Bello, M.L.; Felzenszwalb, I.; Araújo-Lima, C.F.; Macedo, A.F. Vanilla from Brazilian Atlantic Forest: In vitro and in silico toxicity assessment and high-resolution metabolomic analysis of Vanilla spp. ethanolic extracts. Food Chem. 2024, 456, 139948. [Google Scholar] [CrossRef]
  97. Hossain, M.A.; Sohel, M.; Sultana, T.; Hasan, M.I.; Khan, M.S.; Kibria, K.M.K.; Mahmud, S.H.; Rahman, H. Study of kaempferol in the treatment of COVID-19 combined with Chikungunya co-infection by network pharmacology and molecular docking technology. Inform. Med. Unlocked 2023, 40, 101289. [Google Scholar] [CrossRef] [PubMed]
  98. Olatunde, A.; Mohammed, A.; Ibrahim, M.A.; Tajuddeen, N.; Shuaibu, M.N. Vanillin: A food additive with multiple biological activities. Eur. J. Med. Chem. Rep. 2022, 5, 100055. [Google Scholar] [CrossRef]
  99. Bezerra, D.P.; Soares, A.K.N.; De Sousa, D.P. Overview of the Role of Vanillin on Redox Status and Cancer Development. Oxid. Med. Cell Longev. 2016, 2016, 1–9. [Google Scholar] [CrossRef]
  100. Goyal, N.; Do, C.; Sridhar, J.; Shaik, S.; Thompson, A.; Perry, T.; Carter, L.; Foroozesh, M. Design, Synthesis, and Biological Studies of Flavone-Based Esters and Acids as Potential P450 2A6 Inhibitors. Chem. Res. Toxicol. 2023, 36, 1973–1979. [Google Scholar] [CrossRef]
  101. Higashi, E.; Fukami, T.; Itoh, M.; Kyo, S.; Inoue, M.; Yokoi, T.; Nakajima, M. Human CYP2A6 Is Induced by Estrogen via Estrogen Receptor. Drug Metab. Dispos. 2007, 35, 1935–1941. [Google Scholar] [CrossRef] [PubMed]
  102. Higashi, E.; Nakajima, M.; Katoh, M.; Tokudome, S.; Yokoi, T. Inhibitory Effects of Neurotransmitters and Steroids on Human CYP2A6. Drug Metab. Dispos. 2007, 35, 508–514. [Google Scholar] [CrossRef] [PubMed]
  103. Tiong, K.H.; Yunus, N.A.M.; Yiap, B.C.; Tan, E.L.; Ismail, R.; Ong, C.E. Inhibitory Potency of 8-Methoxypsoralen on Cytochrome P450 2A6 (CYP2A6) Allelic Variants CYP2A6*15, CYP2A6*16, CYP2A6*21 and CYP2A6*22: Differential Susceptibility Due to Different Sequence Locations of the Mutations. PLOS ONE 2014, 9, e86230. [Google Scholar] [CrossRef] [PubMed]
  104. Prasopthum, A.; Pouyfung, P.; Sarapusit, S.; Srisook, E.; Rongnoparut, P. Inhibition effects of Vernonia cinerea active compounds against cytochrome P450 2A6 and human monoamine oxidases, possible targets for reduction of tobacco dependence. Drug Metab. Pharmacokinet. 2015, 30, 174–181. [Google Scholar] [CrossRef] [PubMed]
  105. Boonruang, S.; Prakobsri, K.; Pouyfung, P.; Prasopthum, A.; Rongnoparut, P.; Sarapusit, S. Structure–activity relationship and in vitro inhibition of human cytochrome CYP2A6 and CYP2A13 by flavonoids. Xenobiotica 2019, 50, 630–639. [Google Scholar] [CrossRef]
  106. Koenigs, L.L.; Trager, W.F. Mechanism-Based Inactivation of P450 2A6 by Furanocoumarins. Biochemistry 1998, 37, 10047–10061. [Google Scholar] [CrossRef]
  107. Heo, J.-K.; Nguyen, P.-H.; Kim, W.; Phuc, N.; Liu, K.-H. Inhibitory Effect of Selaginellins from Selaginella tamariscina (Beauv.) Spring against Cytochrome P450 and Uridine 5′-Diphosphoglucuronosyltransferase Isoforms on Human Liver Microsomes. Molecules 2017, 22, 1590. [Google Scholar] [CrossRef] [PubMed]
  108. Wang, Y.; Wu, S.; Chen, Z.; Zhang, H.; Zhao, W. Inhibitory effects of cytochrome P450 enzymes CYP1A2, CYP2A6, CYP2E1 and CYP3A4 by extracts and alkaloids of Gelsemium elegans roots. J. Ethnopharmacol. 2015, 166, 66–73. [Google Scholar] [CrossRef] [PubMed]
  109. Kim, I.S.; Kim, Y.; Kwak, T.H.; Yoo, H.H. Effects of β-lapachone, a new anticancer candidate, on cytochrome P450-mediated drug metabolism. Cancer Chemother. Pharmacol. 2013, 72, 699–702. [Google Scholar] [CrossRef] [PubMed]
  110. Deng, Y.; Wang, L.; Yang, Y.; Sun, W.; Xie, R.; Liu, X.; Wang, Q. In Vitro Inhibition and Induction of Human Liver Cytochrome P450 Enzymes by Gentiopicroside: Potent Effect on CYP2A6. Drug Metab. Pharmacokinet. 2013, 28, 339–344. [Google Scholar] [CrossRef] [PubMed]
  111. Yoo, H.H.; Lee, M.W.; Kim, Y.C.; Yun, C.-H.; Kim, D.-H. Mechanism-Based Inactivation of Cytochrome P450 2A6 by Decursinol Angelate Isolated from Angelica Gigas. Drug Metab. Dispos. 2007, 35, 1759–1765. [Google Scholar] [CrossRef] [PubMed]
  112. Muto, S.; Fujita, K.-I.; Yamazaki, Y.; Kamataki, T. Inhibition by green tea catechins of metabolic activation of procarcinogens by human cytochrome P450. Mutat. Res. Mol. Mech. Mutagen. 2001, 479, 197–206. [Google Scholar] [CrossRef] [PubMed]
  113. Tassaneeyakul, W.; Guo, L.-Q.; Fukuda, K.; Ohta, T.; Yamazoe, Y. Inhibition Selectivity of Grapefruit Juice Components on Human Cytochromes P450. Arch. Biochem. Biophys. 2000, 378, 356–363. [Google Scholar] [CrossRef]
  114. Lim, S.Y.M.; Loo, J.S.E.; Alshagga, M.; Alshawsh, M.A.; Ong, C.E.; Pan, Y. In vitro and In silico studies of interactions of cathinone with human recombinant cytochrome P450 CYP(1A2), CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2E1, CYP2J2, and CYP3A5. Toxicol. Rep. 2022, 9, 759–768. [Google Scholar] [CrossRef]
Ijms 25 08031 g001
Figure 1. The active site of CYP450 2A6 variant highlighting residues Asn297 and Ile300 that assist in the correct orientation of nicotine (yellow) with the heme moiety (magenta) in the active site. The crystal structure of the CYP450 2A6 with PDB ID 4EJJ [33] was employed.
Figure 1. The active site of CYP450 2A6 variant highlighting residues Asn297 and Ile300 that assist in the correct orientation of nicotine (yellow) with the heme moiety (magenta) in the active site. The crystal structure of the CYP450 2A6 with PDB ID 4EJJ [33] was employed.
Ijms 25 08031 g001
Ijms 25 08031 g002
Figure 2. PRISMA 2020 flow diagram of the eligibility assessment process applied in the current systematic review.
Figure 2. PRISMA 2020 flow diagram of the eligibility assessment process applied in the current systematic review.
Ijms 25 08031 g002
Ijms 25 08031 g003
Figure 3. Chemical structures of nicotine and representative CYP2A6 inhibitors: 6,7-dihydroxycoumarin [65], myricetin [58], a flavonoid, dipropyl and diallyl sulfides from the organosulfuric group of compounds [80], and the isothiocyanates benzyl isothiocyanate (BITC) and phenethyl isothiocyanate (PEITC) [50].
Figure 3. Chemical structures of nicotine and representative CYP2A6 inhibitors: 6,7-dihydroxycoumarin [65], myricetin [58], a flavonoid, dipropyl and diallyl sulfides from the organosulfuric group of compounds [80], and the isothiocyanates benzyl isothiocyanate (BITC) and phenethyl isothiocyanate (PEITC) [50].
Ijms 25 08031 g003
Table 1. Major chemical groups of natural products with CYP2A6 inhibition.
Table 1. Major chemical groups of natural products with CYP2A6 inhibition.
Group NameScaffolds/Representative Structure No. of CompoundsReferences
IsothiocyanatesIjms 25 08031 i0013[50,51]
TerpenesIjms 25 08031 i0022[52,53]
AlkaloidsDiverse chemical group of organic nitrogen-containing bases5[52,53,54,55,56]
FlavonoidsIjms 25 08031 i00332[57,58,59]
Furanocoumarins/psoralenIjms 25 08031 i0044[60,61,62]
1,4-naphthoquinonesIjms 25 08031 i0055[63]
PropylaminesIjms 25 08031 i0061[60]
TriazolesIjms 25 08031 i0071[64]
CoumarinsIjms 25 08031 i00820[61,65]
ThiophenesIjms 25 08031 i0093[59]
HirsutinolidesIjms 25 08031 i0104[59]
Organosulfur compoundsDiverse group that contains structures with at least one –S atom connected to carbon atoms23[66]
BenzaldehydesIjms 25 08031 i0112[53,67]
Cannabidiol derivatives Ijms 25 08031 i0124[68,69]
BenzodioxolesIjms 25 08031 i0131[70]
Table 2. Studies excluded from the analysis.
Table 2. Studies excluded from the analysis.
ReferenceExclusion Criteria
1[71]Study reports only results from Khat ethanol extract.
2[72]Report about Aconiti Lateralis Radix Praeparata extract (in combination with red ginseng).
3[73]Study of CYP2A6 inhibition from the extracts of Hibiscus sabdariffa. No report of chemical structures and related data.
4[61]The specific study contains data only on in vivo modulation with no inhibitory information on the substances xanthotoxin/bergapten and umbelliferone
5[74]Study reporting the comparison between the plant extract from the mango tree and mangiferin (an ingredient derived from the plant) isolated and purified. Weak inhibition results
6[75]Study reporting the effect of a decoction from Sideritis scardica with no other inhibitory data provided.
7[76]Study presents data from mouse experiments but does not report any inhibitory data for CYP2A6 in the form of % inhibition, IC50 or Ki.
8[77]Study reports the CYP2A6 inhibition by Danhong injection (DHI) extract with no information on specific compounds that may act as inhibitors.
9[78]Study reports the inhibition of CYP2A6 from tropical medicinal herbs with no information on active ingredients.
10[79]Study reports the effect of a decoction from Sutherlandia frutescens but provides no information on specific compounds with inhibitory activity towards CYP2A6.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Tzoupis, H.; Papavasileiou, K.D.; Papatzelos, S.; Mavrogiorgis, A.; Zacharia, L.C.; Melagraki, G.; Afantitis, A. Systematic Review of Naturally Derived Substances That Act as Inhibitors of the Nicotine Metabolizing Enzyme Cytochrome P450 2A6. Int. J. Mol. Sci. 2024, 25, 8031. https://doi.org/10.3390/ijms25158031

AMA Style

Tzoupis H, Papavasileiou KD, Papatzelos S, Mavrogiorgis A, Zacharia LC, Melagraki G, Afantitis A. Systematic Review of Naturally Derived Substances That Act as Inhibitors of the Nicotine Metabolizing Enzyme Cytochrome P450 2A6. International Journal of Molecular Sciences. 2024; 25(15):8031. https://doi.org/10.3390/ijms25158031

Chicago/Turabian Style

Tzoupis, Haralampos, Konstantinos D. Papavasileiou, Stavros Papatzelos, Angelos Mavrogiorgis, Lefteris C. Zacharia, Georgia Melagraki, and Antreas Afantitis. 2024. "Systematic Review of Naturally Derived Substances That Act as Inhibitors of the Nicotine Metabolizing Enzyme Cytochrome P450 2A6" International Journal of Molecular Sciences 25, no. 15: 8031. https://doi.org/10.3390/ijms25158031

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop